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medium, provided the original work is properly cited.Emerging evidence points to aberrant regulation of translation as a driver of
cell transformation in cancer. Given the direct control of translation by tRNA
modifications, tRNA modifying enzymes may function as regulators of cancer
progression. Here, we show that a tRNA methyltransferase 9-like (hTRM9L/
KIAA1456) mRNA is down-regulated in breast, bladder, colorectal, cervix and
testicular carcinomas. In the aggressive SW620 and HCT116 colon carcinoma cell
lines, hTRM9L is silenced and its re-expression and methyltransferase activity
dramatically suppressed tumour growth in vivo. This growth inhibition was linked
to decreased proliferation, senescence-like G0/G1-arrest and up-regulation
of the RB interacting protein LIN9. Additionally, SW620 cells re-expressing
hTRM9L did not respond to hypoxia via HIF1-a-dependent induction of GLUT1.
Importantly, hTRM9L-negative tumours were highly sensitive to aminoglycoside
antibiotics and this was associated with altered tRNA modification levels com-
pared to antibiotic resistant hTRM9L-expressing SW620 cells. Our study links
hTRM9L and tRNA modifications to inhibition of tumour growth via LIN9 and
HIF1-a-dependent mechanisms. It also suggests that aminoglycoside antibiotics
may be useful to treat hTRM9L-deficient tumours.Medicine, Department
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The regulation of translation has primarily been studied at
the level of initiation, with both CAP-dependent and CAP-
independent regulatory mechanisms playing vital roles in
cellular proliferation, stress signalling and cell cycle progression
(Komar & Hatzoglou, 2011; Sonenberg & Hinnebusch, 2009;
Sonenberg et al, 2000). Translation elongation is another
regulatory strategy and, at its core, requires the efficient
interaction of codons and anticodons found on mRNA and
tRNA, respectively. Enzyme catalysed modification of tRNA has
been shown to dramatically affect codon–anticodon interactions
(Murphy et al, 2004; Yarian et al, 2002). Among the tRNA
modifications in eukaryotes, wobble uridine modifications have
been well studied in Saccharomyces cerevisiae, with 11 of 13
tRNAs possessing either 5-carbamoylmethyluridine (ncm5U),
the 20-O-ribose-methylated form ncm5Um, 5-methoxycarbonyl-is an open access article under
on and reproduction in any
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Ulrike Begley et al.methyluridine (mcm5U) or 5-methoxycarbonylmethyl-2-thio-
uridine (mcm5s2U; Johansson et al, 2008). Wobble uridine and
anticodon-associated modifications on tRNA molecules pro-
mote or restrict specific anticodon–codon interactions and can
influence translation speed and fidelity. In fact, the levels of
many modifications associated with the structure of the
anticodon (positions 34 or 37) change in response to cellular
stress, supporting that translation elongation is dynamically
regulated (Chan et al, 2010).
The completion of the wobble uridine modification mcm5U
(a precursor for mcm5s2U) is catalysed by yeast tRNA methyl-
transferase 9 (Trm9) and its mammalian homolog ALKBH8
(Begley et al, 2007; Fu et al, 2010a; Songe-Moller et al, 2010).
Amino acid sequence analyses reveal one gene encoding Trm9
in S. cerevisiae (Trm9) and two Trm9 homologs in mammals
(KIAA1456 and ALKBH8; Fig 1A). Trm9 has been biochemically
characterized. After elongator complex proteins generate the
substrate cm5U, Trm9 uses the methyl donor S-adenosyl
methionine (SAM) to complete the formation of mcm5-based
modifications. Trm9 forms a complex with Trm112 to catalyse
the last step in the formation of mcm5U (Mazauric et al, 2010).
Clarke and coworkers initially characterized Trm9 and demon-
strated that it modifies wobble uridines in specific arginine and
glutamic acid tRNAs. They further showed that Trm9-deficient
yeast cells were sensitive to the translational infidelity inducing
aminoglycoside antibiotic paromomycin (Kalhor & Clarke,
2003). Cells deficient in Trm9 also display sensitivity to DNA
damaging agents (e.g.MMS and IR) and have a damage induced
cell cycle progression defect (Begley et al, 2002, 2004, 2007;
Bennett et al, 2001; Chan et al, 2010).
ALKBH8 is the most thoroughly characterized mammalian
homolog of yeast Trm9 and ALKBH8 deficient cells are sensitive
to DNA damaging agents (Fu et al, 2010a). ALKBH8 makes
the wobble uridine modifications mcm5U and mchm5U. The
formation of mcm5U is required for the completion of the
mcm5s2U, and mcm5Um modifications (Fu et al, 2010a,b;
Songe-Moller et al, 2010; van den Born et al, 2011). Mouse
ALKBH8 has also been implicated in the recoding of stop
codons to promote the incorporation of selenocysteine into
specific proteins (Songe-Moller et al, 2010). Compared to
yeast Trm9, ALKBH8 contains additional 2-oxoglutarate- and
iron-dependent dioxygenase and RNA binding domains. The
second yeast Trm9 homolog identified in mice and humans is
KIAA1456, but there is little functional information associated
with the corresponding proteins. We have tentatively desig-
nated KIAA1456 as hTRM9L (human TRM9-like protein). The
hTRM9L gene encodes a protein that contains an SAM-
dependent methyltransferase domain. Based on domain struc-
ture and protein size hTRM9L is similar to yeast Trm9. In
humans, the hTRM9L gene maps to the end of human
chromosome 8, a region commonly lost or silenced in many
different cancers, including colorectal carcinoma (Ilyas et al,
1999; Kerangueven et al, 1995; Knowles et al, 1993; Prasad et al,
1998). Recent studies have implicated hTRM9L as a potential
tumour suppressor gene (Flanagan et al, 2004). These studies,
conducted in soft agar, demonstrated that a 250mBp piece of
DNA specific to the end of chromosome 8, where hTRM9L andEMBO Mol Med (2013) 5, 366–383 other genes are located, decreased the colony formation of
specific colorectal cancer lines.
Wobble base modifications catalysed by yeast Trm9 and
ALKBH8 proteins play important roles in stress signalling
pathways, with responses to DNA damage and reactive oxygen
species as prime examples (Begley et al, 2007; Chan et al, 2010;
Fu et al, 2010a; Songe-Moller et al, 2010). The potential presence
of a tumour suppressor on chromosome 8, in a region that
encodes hTRM9L, and the linkage between tumour suppressors
and stress signalling pathways led us to postulate that hTRM9L
could play a role in controlling tumour growth. In this study, we
show that hTRM9L is a powerful negative regulator of tumour
growth and that the hTRM9L transcript is significantly down-
regulated in breast, bladder, cervix, testicular and colorectal
carcinomas. Further, we demonstrate that the down-regulation
of hTRM9L is due to epigenetic silencing in advanced colorectal
cancer cell lines. Importantly, re-expression of hTRM9L strongly
inhibits SW620 and HCT116 colon carcinoma cell tumouri-
genicity in vivo via a senescence-like G0/G1-arrest. Further, we
show that inhibition of tumour growth by hTRM9L is dependent
on a functional SAM binding domain. Tumour growth inhibition
by hTRM9L is linked to increased transcription of the RB
interacting protein LIN9 and to a failure of hTRM9L-expressing
cells to mount a hypoxic response. We also demonstrate that the
hTRM9L expressing cells have a significant increase in mcm5U
and other tRNA modifications after paromomycin treatment,
relative to SW620-LacZ and that hTRM9L promotes global
changes in tRNA modification. Finally, we show that loss of
hTRM9L in certain tumours can be exploited as a potential
chemotherapeutic target since its absence renders tumour cells
sensitive to aminoglycoside antibiotics, which induce mis-
incorporation at specific codons leading to protein damage and
selective tumour cell killing.RESULTS
Epigenetic silencing of hTRM9L in human primary cancers
and cancer cell lines
Published evidence and gene expression database mining
suggested that hTRM9L mRNA is down-regulated in human
tumours due to epigenetic gene silencing (Flanagan et al, 2004;
Rhodes et al, 2004). To assess the extent of hTRM9L mRNA
down-regulation in human cancers, we examined a human
tumour panel tissue array, covering 18 different cancer types
with a total of 306 tumours, for the expression of hTRM9L
mRNA. We found that hTRM9L is significantly down-regulated
in testicular, breast and colon cancers followed by cervical and
bladder carcinomas (Fig 1B). The tissue array included colon
cancer tissue samples ranging from stage I through stage IV. The
down-regulation of hTRM9L was more pronounced in stage IV
cancer, suggesting a progressive loss of hTRM9L expression
coincided with the acquisition of a more aggressive phenotype
and perhaps a later event in progression. We next determined
whether hTRM9L down-regulation was preserved in colorectal
cancer cell lines using quantitative real-time PCR. hTRM9
transcripts were not detected in three of five cell lines tested,2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 367
Research Article www.embomolmed.org
hTRM9L suppresses tumour growth
! "
#"
$"
%"
! "#$%&’ () *+, - . &/ 0’ (00&
A B
C E
D
F
Figure 1. hTRM9L transcripts are decreased in many tumour types and the tumourgenicity of SW620 colon cancer cells can be decreased by treatment
with a 5-meC demethylating agent.
A. Annotated gene tree of yeast Trm9 homologs. Two yTrm9 homologs are found in humans, KIAA1456(hTRM9L) and hALKBH8. In addition to the SAM-
dependent Methyltransferase domain, hALKBH8 contains a RNA Recognition Motif and an AlkB domain.
B. KIAA1456 (hTRM9L) expression profiling of Origene Tissue Scan qPCR array covering 18 different cancer types was used to identify significant differences in
expression of hTRM9L in these cancer tissues compared to normal tissues. Significant differences in hTRM9L transcripts were evaluated and scored (Log10 p-
value).
C. hTRM9L expression was analysed in various colorectal cancer cell lines. RNA was isolated from SW620, SW480, HT29, HCT116 and SW1116 cell lines and
hTRM9L transcript levels were quantitated (DDCT method) by qPCR.
D,E. HCT116 or SW620 cells were treated with 10mM5-aza-dC over a period of 7 days with the culture being replaced every 24 hwith fresh containing 5-aza-dC.
RNA was isolated and hTRM9L expression was determined by qPCR analysis.
F. Mock or 5-aza-dC treated SW620 cells (5105) were inoculated on CAM and grown for 7 days in vivo. Tumours were excised, minced and collagenased and
the number of cells per tumour nodule was counted. Statistical significance determined by paired student’s t-test.
368which included HCT116, SW1116 and SW620, while it was
present in HT29 and SW480 cells (Fig 1C). However, hTRM9L
transcript levels were still lower in HT29 cells than in SW480
cells. Thus, colon cancer cell lines were deemed an amenable
model to dissect themechanisms by which hTRM9L is turned off
and to determine how hTRM9L might affect tumour growth. 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.We found that treatment of HCT116 or SW620 cells with
5-aza-deoxycytidine (10mM), which promotes demethylation of
5-methylcytosine to cytosine upon DNA replication, resulted in
the restoration of hTRM9L mRNA expression (Fig 1D and E).
Methylation of tumour suppressors is thought to promote
tumourigenesis (Esteller, 2005; Jones & Baylin, 2002). Thus, weEMBO Mol Med (2013) 5, 366–383
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cells with 5-aza-deoxycytidine would inhibit tumour growth and
whether this correlated with hTRM9L re-expression. SW620
cells were cultured in the presence of 5-aza-deoxycytidine
(10mM) for 7 days before being inoculated on chick embryo
CAMs to monitor their tumourigenicity (Fig 1F). While control
cells produced rapidly growing tumours after 1 week, the 5-aza-
deoxycytidine-treated SW620 cells were strongly inhibited in
their tumourigenic capacity (p¼ 0.00001). We conclude that
hTRM9L expression is either directly or indirectly regulated by
DNA promoter methylation and that hTRM9L expression is
inversely correlated with the tumourigenic capacity of SW620
cells. Cumulatively, our data suggests that hTRM9L might have
a growth inhibitory/tumour suppressive role in certain cancers.
hTRM9L-mediated inhibition of colorectal tumour growth is
an evolutionary conserved function
To functionally link hTRM9L expression to tumourigenicity, we
used a gain of function strategy where SW620 and HCT116 cells
were engineered to over-express hTRM9L. Because the tRNA
methyltransferase activity of Trm9 is conserved from yeast to
mammals, we also engineered SW620 cells with the yeast TRM9
gene (yTrm9) and with mouse Alkbh8. Both the cancer cells
and the respective controls expressing LacZ were tested for
tumourigenic capacity in the CAM (SW620) or nude mice
(SW620 and HCT116) systems. In contrast to parental, LacZ- or
GFP-expressing SW620 cells, re-expression of hTRM9L, yTrm9
or Alkbh8 caused a dramatic inhibition of SW620 tumour
growth on CAMs (Fig 2A–C). Injection of hTRM9L-expressing
SW620 or HCT116 cells in the subcutaneous tissue of nude mice
showed that re-expression of this gene resulted in a strong
inhibition of tumour growth. In SW620, relative to LacZ,
hTRM9L expressing cells had an extended latency that lasted for
an additional week (Fig 2D) and these cells slowed down their
growth rate after tumour take. This inhibition of tumour growth
was reflected in a significant reduction in the final tumour mass
volume compared to control LacZ cells (Supporting Information
Fig S1A) and this was not only observed for SW620 cells but also
when comparing HCT116-LacZ versus -hTRM9L cells (Fig 2E).
We further used the SW620 model to test whether restored
growth of hTRM9-expressing cells was due to loss of the
transgene. To this end we tested for hTRM9L expression in the
tumours that grew in vivo and we found no correlation between
the presence of hTRM9L and the growth rate and size of the
tumours that grew in the hTRM9L group (Supporting Informa-
tion Fig S1B). Thus, other mechanisms might allow SW620 cells
to eventually bypass the hTRM9L inhibitory function.Figure 2. Re-expression of hTRM9L and like methyltransferases in SW620 cel
A. 5105 SW620 cells expressing either LacZ or hTRM9L were inoculated on C
minced and collagenased and the number of cells per tumour nodule was
B,C. Experiments similar to A were performed with (B) yTrm9 and (C) mouse Alk
D,E. SW620 cells expressing either LacZ or hTRM9L were inoculated in nude mice
days is plotted in (D) and day 11 data for all tumours is shown in (E). HCT1
tumours were measured every 2 days, with 12-day data shown.
F. SW620 cells expressing either LacZ, hTRM9L or its single amino acid mutants
and tumours were analysed after 7 days. Tumours were excised, minced an
EMBO Mol Med (2013) 5, 366–383 To assess whether the methyltransferase activity predicted
for hTRM9L was required for the inhibition of tumour growth,
we individually mutated two amino acids (D91R and I108N)
found in hTRM9L’s evolutionarily conserved methyltransferase
domain (Kalhor & Clarke, 2003; Katz et al, 2003). Due to
their interaction with and use of SAM as a co-factor, most
methyltransferase enzymes share this conserved domain
structure consisting of three motifs (I-III) that bind and position
SAM near the active site. hTRM9L, ALKBH8 enzymes and
yeast Trm9 have all been reported to contain these conserved
methyltransferase motifs (Kalhor & Clarke, 2003; Songe-
Moller et al, 2010) and each enzyme has identical amino acids
at positions 91 and 108. We also mutated an amino acid
in the unassigned C-terminal region (R410E) of hTRM9L
(Supporting Information Fig S1C). The resulting hTRM9L
mutants (D91R, I108N and R410E) were then assessed on
CAM-based xenografts, relative to SW620 cells expressing LacZ
or wild-type hTRM9L. Mutations to the SAM binding domain
(D91R and I108N) abolished the hTRM9L dependent growth
suppression phenotype, while the R410E mutation outside the
SAM binding domain had little effect (Fig 2F). Together the
structure–function results support the idea that SAM binding
and methyltransferase activity specific to hTRM9L is required
for inhibition of tumour growth. Ultimately, our data reveal a
previously unrecognized and unanticipated growth-inhibitory
function of the methyltransferase activity of hTRM9L.
hTRM9L induces tumour growth inhibition via a senescence-
like arrest
We next explored whether the growth inhibition caused by
hTRM9L was due to the induction of apoptosis, autophagic cell
death and/or to a growth arrest-associated phenotype. Tumour
nodules produced by SW620-LacZ or SW620-hTRM9L cells
after a week in vivo were sectioned and stained for cleaved
caspase-3 (Fig 3A), an apoptosis marker. This staining revealed
no major difference in caspase-3 levels, which were overall
<7.5%, in the hTRM9L positive or negative tumours (Support-
ing Information Fig S2A). This suggests that the induction of
apoptosis is not a major pathway by which hTRM9L expressing
cells promote growth inhibition. Staining for LC3-I/II to
detect any evidence of autophagic cell death also revealed
low basal levels of signal (<5%) that did not differ significantly
between SW620-LacZ and SW620-hTRM9L tumour nodules
(Fig 3B and Supporting Information Fig S2B). These findings
suggest that hTRM9L is not inducing gross changes in apoptotic
or autophagic cell death that would account for the growth
inhibitory function.ls inhibits tumour growth in vivo.
AM and tumours were analysed after 7 days in vivo. Tumours were excised,
counted.
bh8.
and tumours were measured every 2 days, up to 11 days. Average data for all
16 cells expressing either LacZ or hTRM9L were inoculated in nude mice and
hTRM9L-D91R, hTRM9L-I108N and hTRM9L-R410E were inoculated on CAM
d collagenased and the number of cells per tumour nodule was counted.
"
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Figure 3. hTRM9L dependent growth suppression is associated with increased cellular senescence.
A–E. Tumour nodules of SW620 parent, LacZ and hTRM9L expressing cells were harvested 7 days post-inoculation, fixed and prepared for (A) cleaved caspase 3,
(B) LC-3 (C) phospho-Histone3 (pH3), (D) p21 and (E) p27 immunohistochemistry.
F. SW620-GFP and hTRM9L expressing cells from tumour nodules were harvested after several time points as indicated and stained for acidic b-gal. Statistical
significance determined by paired student’s t-test.The detection of proliferation markers revealed that hTRM9L
expression in SW620 cells caused a marked decrease in histone-
3 phosphorylation (p¼ 0.05) at Ser-10 (Fig 3C and Supporting
Information Fig S2C) a residue that is modified during G2-M
transition and reveals active transition through this phase.
These results support that SW620-LacZ cells are actively
proliferating, while SW620-hTRM9L cells are proliferating
slowly or not at all. We also detected a consistent up-regulation
of the cell cycle inhibitor p21, (p¼ 0.01, Fig 3D and Supporting
Information Fig S2D), but found no change in p27 expression in
hTRM9L tumour nodules (Fig 3E). The combined effect of
p21 induction and reduced P-H3 levels suggests that hTRM9L
is inducing a growth arrest phenotype. We next monitored
senescence-associated b-galactosidase (SA-b-Gal) activity,
heterochromatin protein 1g (HP1g expression and presence
of histone-3-tri-methyl-Lysine-9 marks, all senescence markersEMBO Mol Med (2013) 5, 366–383 (Narita et al, 2006; Sang et al, 2008; Xue et al, 2007; Zhang et al,
2007), in SW620-Control (GFP) or SW620-hTRM9L tumour
nodules or after their digestion using collagenase-I. In these
experiments, independent batches of control (GFP) or hTRM9L
expressing cells were generated to allow for b-galactosidase
activity measurements. We analysed b-galactosidase activity
derived from either SW620-Control (GFP) or SW620-hTRM9
in 1-week old tumour nodules (Fig 3F) and found that there
was a strong up-regulation of SA-b-Gal activity in SW620-
hTRM9L cells, relative to SW620-GFP, with 30% of the
hTRM9L proficient and 5% of the control cells expressing SA-
b-Gal, respectively. Although some inter-experiment variability
was observed for the absolute levels of senescence, hTRM9L-
expressing tumour nodules were consistently higher in SA-b-Gal
activity and peaked 3 days after in vivo inoculation. Close to
80% of the hTRM9L proficient cells stained positive for SA-b-Gal2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 371
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372activity after 3 days and up to 7 days in vivo, with a maximum
of 40% of the control cells staining positive for SA-b-Gal
activity 5-days post inoculation (Supporting Information
Fig S2E). However, we detected no difference in HP1g staining,
that displayed a nuclear signal in both SW620-GFP or SW620-
hTRM9L cells in tumour histological sections (Supporting
Information Fig S2F). We also detected very low levels of
H3K9me3 marks in these tumour sections when comparing
the same cells lines (Supporting Information Fig S2F). Our
results reveal that hTRM9L-induced tumour growth inhibition
in SW620 cells is not due to increased apoptosis or autophagy;
rather it is caused by a growth arrest phenotype that only
partially recapitulates the expression of key markers of a
canonical senescence phenotype (Collado & Serrano, 2006;
Narita et al, 2006; Xue et al, 2007). Thus, hTRM9L is able to
induce a ‘‘senescence-like phenotype’’ associated with SA-b-gal
activity and p21 expression up-regulation that is strongly
associated with a G0/G1 arrest.
hTRM9L-dependent up-regulation of the tumour suppressor
LIN9 is linked to the growth inhibitory phenotype
The fact that SW620 cells are derived from a metastatic lesion
and that SW480 cells are derived from the primary tumour
from the same patient opened the possibility that hTRM9L
might affect metastatic capacity related to invasion and
dissemination. However, we did not find any clear indication
that hTRM9L affects intravasation or dissemination to the
liver in the chick embryo metastasis assay (Supporting
Information Fig S3A and S3B), suggesting that loss of hTRM9L
in the SW620 metastatic variant is not related to gain of
invasion and dissemination properties in these cells. Time
course analysis of CAM in vivo tumour growth revealed that
3 days after inoculation, the hTRM9L deficient cells begin to
proliferate while the hTRM9L proficient cells are already in
the senescence-like arrest (Fig 4A). Thus, within 24–48 h after
injection, SW620-hTRM9L cells are unable to mount a strong
proliferative behaviour and at day 3 this phenotypic discrepancy
is significant. We performed gene expression profiling of
SW620-LacZ and SW620-hTRM9L using the Affymetrix plat-
form, to identify the signalling pathways affected by hTRM9L.
We took advantage of the GFP tagging present in SW620
and sorted cells from 3-day-old tumour nodules using FACS,
as this is when SW620-LacZ cells begin actively proliferating
and SW620-hTRM9L cells are arrested. This strategy revealed
significant changes in gene expression in only a small subset
of genes that were up-regulated (25-transcripts) or down-
regulated (37-transcripts) in hTRM9L expressing cells, relative
to LacZ (Fig 4B, Table 1). The magnitude of gene expression
change was not larger than threefold (except for hTRM9L in
the SW620-hTRM9L cells). We validated these findings for
a subset of transcripts to confirm the increase levels for POR,
LIN9 and hTRM9L and decreased ALAS1 levels in hTRM9L-
expressing cells (Fig 4C). Thus, it appears that only a limited
number of genes are regulated at the transcriptional level by
hTRM9L, and that they need not change dramatically in
transcriptional abundance to associate with a strong growth
inhibition. 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.Among the genes induced by hTRM9L, we identified the
tumour suppressor LIN9, a mammalian homolog of the C.
elegans LIN9 protein that is part of the transcriptional repressor
DREAM complex (also known as the LINC complex) (Pilkinton
et al, 2007a; Sandoval et al, 2009). We validated that the
LIN9 transcript and protein is up-regulated 2-fold in hTRM9
expressing cells (Supporting Information Fig S3C) and reasoned
that this could be one of the pathways used by such cells to
induce growth arrest in xenografts. LIN9 has been demonstrated
to act as a tumour suppressor itself as it can bind to pRB (Gagrica
et al, 2004).We reasoned that if increased LIN9 expression in the
hTRM9L expressing cells was responsible for the corresponding
growth suppressive phenotypes in xenografts, then a knock-
down of LIN9 in hTRM9L expressing cells should restore the
proliferative phenotype associated with SW620 parental or LacZ
expressing cells. Using specific shRNAs, we obtained 93%
knockdown of LIN9 in hTRM9L expressing SW620 cells
(Supporting Information Table 1). We inoculated the parental
and LIN9 knockdown cells and analysed for tumour formation
on the CAM at 7 days. We found that knockdown of LIN9
completely reverses the hTRM9L phenotype and significantly
increases the proliferation of SW620-hTRM9L expressing cells
(p¼ 0.0001), relative to a scrambled knockdown (Fig 4D).
Knockdown of LIN9 in SW620-lacZ cells did not show any
significant effect on cell proliferation. Our experiment results
associated with LIN9 loss of function in hTRM9L expressing
SW620 cells, clearly demonstrate that part of the mechanism of
tumour growth inhibition involves a known component of the
DREAM complex and cell cycle machinery.
hTRM9L expression prevents tumour growth under hypoxic
conditions in SW620 cells
The tumour microenvironment can include multiple cellular
stresses, with hypoxia being an underlying theme. We
postulated that adaptation to low oxygen levels might be one
of the triggers associated with the hTRM9-dependent growth
suppression. To test our hypothesis, we cultured SW620-LacZ
and SW620-hTRM9L cells under normoxic (21% O2) and
hypoxic (1%O2) conditions for 12 days. We determined that the
number of colonies derived from SW620-hTRM9L expressing
cells was significantly reduced when cells were cultured under
hypoxic conditions, relative to SW620-LacZ (Fig 5A and B).
This result was in contrast to the observation that both cell
types can form similar numbers of colonies under normoxic
conditions. A key response pathway operating under hypoxic
conditions is controlled by HIF1-a, a transcription factor that is
stabilized and targeted to the nucleus in response to decreased
O2 levels (Lisy & Peet, 2008; Yee Koh et al, 2008). In our CAM
xenograft model, we tested whether the HIF1-a pathway was
perturbed in hTRM9L expressing cells, relative to SW620-LacZ.
First, we performed a quantitative analysis of HIF1-a protein
levels in SW620, SW620-LacZ and SW620-hTRM9L expressing
cells grown 3 days post inoculation on the CAM (Fig 5C). We
determined that HIF1-a protein levels were 2-fold higher in
hTRM9L expressing cells, relative to LacZ, a finding that was
surprising as these cells fail to grow under hypoxic conditions
or on xenografts. The increased HIF1-a levels indicated that theEMBO Mol Med (2013) 5, 366–383
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Figure 4. LIN9 transcripts are up-regulated in hTRM9L expressing cells and are responsible for the growth suppression phenotype.
A. SW620 (blue circle), LacZ (green square) and hTRM9L (red triangle) tumours were harvested after several time points as indicated, minced, collagenased and
quantitated as before.
B. The intensity values measured by microarray analysis are represented in a scatter plot comparing expression patterns of SW620-LacZ (x-axis) and SW620-
hTRM9L (y-axis) of 3-day-old tumours grown on the CAM. Each gene in the microarray is represented by a dot with coordinates consisting of average gene
expression measured from three different replicates of RNA samples. A linear regression line is overlaid with the scatter plot and the regression equation is
displayed. Outliers represent up-regulated or down-regulated genes.
C. Real-time PCR validation of POR, LIN9, ALAS1, and hTRM9L respective expression levels. RNA was isolated from a GFP-positive population isolated from 3 day
tumours grown on the CAM and amplified using MessageBOOSTERTM cDNA Synthesis Kit. Relative quantification is presented after normalization with GAPDH.
D. Cells with a knock down of LIN9 or a scrambled control, in hTRM9L and LacZ expressing variants, were assayed for their tumour forming capacity, alongwith the
parental cells. Statistical significance determined by paired student’s t-test.initial response to hypoxic conditions is mounted in hTRM9L
expressing cells but that it might be over-compensating because
downstream signals are not activated. We monitored HIF1-a
nuclear localization under hypoxic conditions and determined
that nuclear localization was occurring at similar levels (65%)
in both hTRM9L and LacZ expressing cells (Fig 5D). These data
suggest that the ability of HIF1-a to become translocated into the
nucleus upon hypoxia is not a limitation. To determine if nuclear
localized HIF1-a was somehow inactive in hTRM9L expressing
cells, we used immunohistochemistry to monitor the in vivo
expression of GLUT1, a prototypical hypoxia and HIF1-a target
gene (Chen et al, 2001). In each case, we counted 400 stained
SW620 cells expressing LacZ or hTRM9L and observed a highly
significant difference (p¼ 0.0009) in GLUT1 expression. We
found that while control SW620-LacZ cells were able to express
high levels of GLUT1 (75%) that clearly localized to the plasma
membrane, SW620-hTRM9 tumour sections showed a markedEMBO Mol Med (2013) 5, 366–383 decrease in GLUT1 expression (5%) that was irregularly
distributed in a membrane-like pattern (Fig 5E). There was a
significant difference (p¼ 0.0009) in the number of GLUT1
positive cells whenwe compared SW620-LacZ to those expressing
hTRM9L (Supporting Information Fig S4).We conclude that while
HIF1-a appears to be responsive to O2 tensions, this does not
correlate with efficient GLUT1 protein accumulation, which is
required to adapt to the demands of a hypoxic microenvironment.
Loss of hTRM9L in human tumours allows for selective killing of
cancer cells with the translational error inducer paromomycin
A deficiency in yeast Trm9 renders cells sensitive to the
aminoglycoside antibiotic paromomycin (Kalhor & Clarke,
2003). Complementation analysis demonstrated that re-expres-
sion of either hTRM9L, human ALKBH8, or yTrm9 in trm9D
S. cerevisiae cells could rescue the paromomycin sensitive
phenotype (Fig 6A). We note that ALKBH8 provided more2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 373
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Table 1. Transcripts regulated in SW620-hTRM9L versus SW620-LacZ cells (log2-based fold change)
374rescue then hTRM9L, with neither activity rescuing to levels
demonstrated by yTrm9. Next using these yeast systems, we
performed quantitative LC-MS/MS analysis on purified tRNA
derived fromwild-type, trm9D and trm9D cells expressing either 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.yTRM9, hALKBH8 or hTRM9L. The trm9D yeast represents a
ideal model as these mutants have been shown to be devoid of
mcm5U and mcm5s2U modifications (Chan et al, 2010) while
providing the yTrm9 substrate cm5U, which we have confirmedEMBO Mol Med (2013) 5, 366–383
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Figure 5. Hypoxic growth prevented in hTRM9L re-expressing cells.
A,B. SW620-LacZ (light grey bars) and SW620-hTRM9L (dark grey bars) expressing cells were grown under 21% oxygen (normoxic) and 1% oxygen (hypoxic)
conditions and the colonies formed were quantitated. No apparent growth difference on the cell lines was detected when grown under normal oxygen
conditions, whereas exposure to hypoxia revealed a growth-sensitive phenotype of hTRM9L expressing cells.
C. Protein lysates prepared from 3-day-old tumours were added to MSD MULTI-SPOT 4-Spot plates coated with anti-total-HIF1-a antibody. Total HIF1-a was
detected with anti-total-HIF1-a antibody labeled with MSD SULFO-TAG reagent. hTRM9L expressing tumour cells show a twofold increase in HIF1-a protein
levels compared to control tumour cells.
D. Immunofluorescence microscopy analysis of HIF1-a in hTRM9L deficient and proficient cells under normoxic and hypoxic conditions. Images were not fixed
in exposure time, thus, they do not reflect the quantitative protein abundance difference shown in (C).
E. Levels of downstream markers for HIF1-a target activation, GLUT1, were analysed in both cells types.(Supporting Information Tables 2 and 3). We quantified the
levels of 28 modifications, which included intermediaries in the
mcm5U andmcm5s2U biosynthetic pathways, as well as 22 other
tRNA modifications. The mcm5U and mcm5s2U modifications
were only identified in wild-type, trm9Dþ yTrm9 and
trm9Dþ hALKBH8 cells, with hALKBH8 only being able toEMBO Mol Med (2013) 5, 366–383 generate a fraction of what we observed for wild-type cells.
Notably, we observed a significant decrease in the levels of the
cm5U substrate in both hALKBH8 (p¼ 0.002) and hTRM9L
(p¼ 0.006) expressing cells, relative to the trm9D cells, supporting
the idea that both of these activities affect this yTrm9 substrate.
Surprisingly, in hTRM9L-expressing cells we observed significant2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 375
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Figure 6. hTRM9L affects tRNA modification and prevents aminoglycoside antibiotic induced death.
A. Complementation analysis of trm9D yeast cells with hTRM9L, hALKBH8 and yTrm9.
B. Hierarchical clustering of tRNAmodification data, with significance calculated relative to trm9D cells. tRNA modification increases were assigned a positive p-
value, while decreases were assigned a negative p-value.
C. SW620-lacZ and SW620-hTRM9L cells were left untreated or exposed to 1.5mg/ml paromomycin for 24 h. For data reported in (B) and (C), small RNA was
isolated and validated to be of high integrity by Bioanalyser analysis. RNA was enzymatically digested to nucleosides and the identity and levels, as determined
by total ion count (TIC), of specific modified nucleosides was determined by LS/MS-MS analysis.
D. SW480 and SW620 cells were treated with paromomycin and the percent viability for each was determined by trypan blue staining 24 h post exposure.
E. SW620-LacZ and SW620-hTRM9L cells were exposed to paromomycin and assays were performed as described above.
376increases in the levels of 11 other tRNA modifications (Am, Cm,
Gm, I, m1A, m22G, m
2G, m3C, m5C, m7G and yW), relative to
trm9D cells, with 10 of the 11 also significantly up-regulated in
hALKBH8-expressing cells. Our data suggest that both mcm5U/
mcm5s2U and global reprogramming of tRNA modifications
provide paromomycin resistance in yeast, which is a novel finding.
Next, we postulated that hTRM9L re-expressionwould perhaps
have a similar effect on human cells and promote a change in 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.tRNAmodification. Further as ALKBH8 is present in SW620 cells,
the presence of hTRM9L may promote an increase in mcm5U
levels. Based on the yeast rescue data these changes should be
prominent under translational stress conditions. We performed
quantitative LC-MS/MS analysis on purified tRNA derived from
SW620-LacZ and SW620-hTRM9L cells left untreated or exposed
to paromomycin. We quantified the levels of 26 tRNA modifica-
tions from the four sample types (Supporting Information Tables 4EMBO Mol Med (2013) 5, 366–383
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Ulrike Begley et al.and 5). Under untreated conditions, we observed a significant
increase in 10 tRNA modifications (ac4C, Cm, Gm, I, i6A, m1A,
m2G, m5Um, OHyW and t6A) in hTRM9L-expressing cells,
relative to LacZ. We also observed a significant increase in the
levels of 4 tRNA modifications (ac4C, m1A, mcm5U, t6A) in
hTRM9L-expressing cells after paromomycin treatment, relative
to paromomycin treated SW620-LacZ. Paromomycin treatment
leads to a significant decrease (p¼ 0.001) inmcm5U (the ALKBH8
specific modification) levels in SW620-LacZ cells. In contrast,
there was a 20% increase (p¼ 0.05) in mcm5U modifications in
SW620-hTRM9L expressing cells after paromomycin treatment,
relative to untreated (Fig 6B). Our functional analysis supports the
idea that hTRM9L can promote an increase in mcm5U levels
and other tRNA modifications, but the former might be more
prominent under translational stress. This suggested that the loss
of hTRM9L might render tumours less adaptable to drugs that
induce translational stress and perhaps drugs like paromomycin
might selectively affect tumours where hTRM9 is silenced.
To test this possibility, we next determined whether a
deficiency in hTRM9L was associated with sensitivity to
paromomycin in human cells. To initially make this comparison,
we used SW620 metastatic (hTRM9L-) and SW480 primary
tumour (hTRM9Lþ) cells that are derived from the same patient
providing a relatively isogenic system. When SW620 cells
(hTRM9L) and SW480 cells (hTRM9Lþ) were tested for
sensitivity to paromomycin (Fig 6C), we determined that the
hTRM9L deficient cells (SW620) had decreased viability relative to
their hTRM9 proficient counterparts (SW480). We also found that
re-expression of hTRM9L in SW620 cells rescued the sensitivity to
this aminoglycoside antibiotic (Fig 6D). There appears to be a low
threshold for sensitivity to paromomycin in hTRM9L-deficient
cells. Further, there is little difference in paromomycin sensitivity
when comparing SW480 to SW620-hTRM9L expressing cells
(Supporting Information Fig 5). In the SW620 background, theHypoxia  
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EMBO Mol Med (2013) 5, 366–383 sensitivity of hTRM9L deficient, versus proficient, cells was
also observed using the aminoglycoside antibiotic gentamicin
(Supporting Information Fig 6). In addition, HT29 and HCT116
cells expressing hTRM9L were resistant to paromomycin, relative
to LacZ expressing cells (Supporting Information Fig 6B and C).
We conclude that a lack of hTRM9L, and possibly due to the
inability of cells to modulate the levels mcm5U and other tRNA
modifications, may represent a deficiency in tumours that might
be specifically exploited to induce killing of these tumour cells.DISCUSSION
Our study reveals a previously unrecognized function for the
hTRM9L gene in regulating stress adaptation and tumour
growth. We propose the following working model to account
for hTRM9L’s influence on cancer cell proliferation (Fig 7).
hTRM9L, via its methyltransferase activity, likely influences
the translation of a specific protein or proteins involved in the
regulation of LIN9. While there are only a few published reports
that give attention to LIN9 (Gagrica et al, 2004; Osterloh et al,
2007; Pilkinton et al, 2007a,b; Reichert et al, 2010; Sandoval
et al, 2009), there is a clear connection between LIN9 and cell
cycle regulation. In our system, activation of LIN9 in hTRM9L
expressing cells is connected to the onset of a G0–G1 arrest
and a senescence-like phenotype, which accounts for the non-
proliferative phenotype. That not all markers of senescence
were induced by hTRM9L expression is not unexpected as
senescence is a restrictive mechanism that is evaded early
during tumour progression (Beausejour et al, 2003; Narita et al,
2006; Xue et al, 2007). One possible explanation is that hTRM9L-
dependent induction of LIN9, in addition to inhibiting exit from
G1, short circuits the response to hypoxia and prevents cells
from thriving in the oxygen poor tumour microenvironment. Asor suppression 
nescence-like) 
 
Figure 7. Proposed mechanism of growth
suppression in hTRM9L proficient cells.
Direct or indirect regulation of LIN9 and the hypoxic
response lead to decreased tumour growth in
hTRM9L positive cells.
2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 377
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378part of our study, we have identified a disconnect between the
translocation of HIF1-a into the nucleus and the transcriptional
regulation of corresponding targets (i.e. GLUT1). It is possible
that in the hTRM9L cells LIN9 up-regulation could directly or
indirectly interfere with HIF1-a to prevent transcription of
downstream genes.
Modifications of tRNA bases can provide an additional level of
gene regulation and have been shown to regulate the levels of
specific proteins. Yeast Trm9 enhances the translation and levels
of the AGA and GAA codon rich transcripts corresponding to the
ribonucleotide reductase large subunits to promote an efficient
response to DNA damage (Begley et al, 2007). Klungland and
coworkers have provided evidence that mouse Alkbh8 and the
catalysed mcm5U wobble base modifications are vital for the
translation of the reactive oxygen species detoxifying proteinGpx1
(Songe-Moller et al, 2010). Optimization of Gpx1 levels appears to
be working by stop codon recoding to selenocysteine.
The protein sequence for hTRM9L, structure-function results
as well as the complementation and tRNA modification analysis
data support that the corresponding activity can affect tRNA
modification. Clearly though, the hTRM9L-associated paromo-
mycin rescue of trm9D yeast cells is not due to the formation of
mcm5U and mcm5s2U and appears to be due to some global
reprogramming of tRNA modifications. In addition, our yeast
data supports the idea that ALKBH8 is the main tRNA
methyltransferase used for mcm5U and mcm5s2U formation.
While the exact biochemical activity of hTRM9L is still in
question, our yeast tRNA modification data does demonstrate
significant changes to many methyl-based modifications as well
as a decrease in the cm5U substrate. Our global tRNA
modification data in mammalian cancer cells also demonstrates
that under basal conditions the SW620 hTRM9L expressing
cancer cells have a distinct difference in the levels of 11 tRNA
modifications, relative to SW620-LacZ that we have linked to a
growth suppressive signal in cancer cells. Our paromomycin
treatment results in SW620 cells further implicates wobble base
modifications as being vital to the response. Notably, paromo-
mycin treatment leads to a significant reduction in mcm5U,
as well as to an increase in m5C and I modifications, in
SW620-LacZ expressing cells, relative to untreated cells. These
paromomycin-induced changes in tRNA modification were
counteracted in SW620-hTRM9L expressing cells. Importantly,
in SW620-hTRM9L cells there was increased mcm5U levels after
paromomycin treatment, compared to treated SW620-LacZ,
supporting a role for hTRM9L in wobble base modification. This
along with results from our structure-function studies suggests
that stress-induced signals activate the methyltransferase
activity of hTRM9L. Further experimentation is clearly needed
to clarify the precise biochemical activity of hTRM9L. The
absence of mcm5U and mcm5s2U modifications in trm9D cells
expressing hTRM9L, suggests that hTRM9L catalyses the
formation of another modification, works on specific tRNA to
generate mcm5U modifications, regulates other tRNA methyl-
transferases or requires activation or cofactors present in
mammalian but not in yeast cells. Identifying the specific
biochemical activity and tRNA substrates as well as the targets
of translational regulation linked to hTRM9L is needed to 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.understand the role that this enzyme plays in tumour growth
suppression.
Colorectal cancer is a result of a multistep process derived
from cumulative gene alterations arising from genome instabil-
ity and epigenetic modifications (Ilyas et al, 1999). The
hypermethylation of CpG islands in promoter regions of many
genes, such as tumour suppressors, that can block transcription
initiation and alter chromatin structure results in gene
expression changes leading to cancer development (Esteller,
2002). Our study putatively links transcriptional silencing of
hTRM9L to changes in translational and transcriptional
potential that would favour tumour growth. While our
experimental model was focused on colorectal cancer, we also
observed a significant decrease in hTRM9L expression levels in
cancers found in the testis, breast, cervix and bladder. Thus,
silencing or loss of hTRM9L may be a more widespread
mechanism that allows cancer cells to progress to a more
aggressive state. The finding that hTRM9L results in the
induction of LIN9 suggests that regulation of translation
elongation via tRNA modifications is a key control point-
regulating exit from G1. Elucidation of the hTRM9L regulatory
pathway and of the players involved, as well as their link to the
stress-induced suppression of the hypoxic response, might open
a previously unrecognized paradigm of rapid signalling from
translation elongation to the G1–S transition of the cell cycle.
Knowledge gained from our aminoglycoside-basedmechanistic
studies identified a potential ‘Achilles’ heel’ for hTRM9L deficient
tumours, in that they are highly sensitive to drugs that induce
translational errors. The absence of hTRM9L leads to a sensitivity
to paromomycin, a finding that can be exploited to specifically
target hTRM9Lnegative/low tumour cells. Thus, during progression,
a growth advantage gained from hTRM9L silencing creates a
phenotype that under specific stresses (i.e. translational) might
become lethal. However, tumours might not encounter this stress
in a sufficient degree that it is detrimental for their growth. A
similar weakness is found in tumours that rely heavily on AKT
signalling from growth factors. Increased AKT signalling is at
the expense of ROS detoxifying capacity because of FOXO3a
inhibition byAKT (Dolado&Nebreda, 2008; Nogueira et al, 2008).
Thus, AKThigh/FOXO3alow tumours become highly sensitive
to ROS inducing drugs. Similarly, because hTRM9Llow tumours
become sensitive to paromomycin, additional drugs could be used
to exploit this weakness in the clinical setting. Aminoglycoside
antibiotics are an attractive class of drugs because many of the
over 25 varieties are approved by the Food and Drug Adminis-
tration (FDA) in the treatment of infections by gram-positive
bacteria (Brunton et al, 2005). We propose that elucidation of
the mechanism by which hTRM9L activity affects translation
and paromomycin sensitivity may allow us to exacerbate this
translational error phenotype for therapeutic purposes.MATERIALS AND METHODS
Cells, culture conditions and treatments
The human colorectal cancer cell lines SW620, SW480, HT29, HCT116
and SW1116 were purchased from ATCC. SW620, HT29 and HCT116EMBO Mol Med (2013) 5, 366–383
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supplemented with 10% FBS (Sigma), 100units/ml penicillin and
100mg/ml streptomycin (Hyclone) at 378C in 5% CO2 humidified air.
SW480 and SW1116 cell lines were cultured in Leibovitz’s L-15
Medium (ATCC) at 378C in 100% humidified air. All in vitro
experiments were performed at 60–70% cell density to avoid the
effects of confluence. For epigenetic reprogramming experiments,
SW620 cells were treated with 10mM 5-aza-dC (Sigma–Aldrich) over
a period of 7 days with the culture being replaced every 24 h with
fresh growth media containing 5-aza-dC. We note that we did not
observe any significant difference in cellular proliferation or viability
when compared to SW620-LacZ and SW620-hTRM9L expressing lines
grown in cell culture. Further, after 5-aza-deoxycytidine treatment, we
did not observe any appreciable toxicity in either of the cell lines. For
the aminoglycoside antibiotic viability assay, SW620 and SW480 cells
were treated with Paromomycin Sulfate or Gentamicin Sulfate
(Sigma–Aldrich) for 24 h and viability was determined by the trypan
blue exclusion method. Yeast experiments were performed using
BY4741 cells. The KIAA1456, mALKBH8, hALKBH8 and yTRM9 genes
were PCR amplified with 40 base pair overhangs, directed to 40 base
pairs upstream and 40 base pairs downstream of the native TRM9
locus. Each construct was targeted to the native TRM9 locus by
transforming into trm9D cells, which were generated with a URA3
deletion cassette. Transformants were selected on 5-FOA plates and
targeting was confirmed by PCR. Site directed mutagenesis of hTRM9L
was performed using PCR based approaches and verified by DNA
sequence analysis. The primers were designed to replace the
appropriate bases to change the aspartic acid (GAC) to arginine
(AGA) at position 91 (D91R mutant), and isoleucine (ATA) to asparagine
(AAT) at position 108 (I108N mutant) and arginine (CGC) to glutamic
acid (GAG) at position 410 (R410E mutant). Stable SW620
cells expressing each hTRM9 mutant construct were made by
retroviral transduction described below.
Production of stable cell lines
The hTRM9L cDNA sequence was PCR-amplified from a
c8orf79 bacterial clone purchased from ATCC, subcloned into a Flag
Tag Expression vector (pCMV-3X FLAG) (STRATAGENE); 3X FLAG
hTRM9L was then cloned into retroviral expression vector pBabePuro
(Addgene). The retroviral expression vector pBabePuro-b-galactosidase
was a generous gift from Dr. Conklin (CRC, SUNY Albany). EGFP was
PCR-amplified from pMSCV sinpuro-EGFP and cloned into pBabeHygro
(Addgene). Each retroviral expression construct was transfected into
Phoenix-Ampho packaging cells by using Fugene6 Transfection
reagent (Roche Applied Science). After 72 h, the retrovirus-containing
supernatant was collected and filtered through a 0.45mm filter to
remove cellular debris. SW620 cells were infected with the viral
supernatant/polybrene mixture (8mg polybrene per millilitre viral
supernatant). Three days post-infection, the infected cells were
selected for using puromycin (2.5mg/ml, MP Biochem.) and hygro-
mycin (800mg/ml, Roche) for 7 days, after which stable cell lines
were expanded. HCT116 and HT29 lines expressing hTRM9L or LacZ
were constructed as described above. LIN9 knockdowns in SW620
LacZ and hTRM9L expressing cells were achieved by stable retroviral
infections. pRS shRNA expression vectors against LIN9 and scrambled
control were purchased from Origene. Retroviruses (pRS/HuSH Lin9
and pRS/HuSH scrambled) were produced in Phoenix-AmphoEMBO Mol Med (2013) 5, 366–383 packaging cells and cell lines were first infected with the viral
supernatant and then selected with the appropriate antibiotic as
described above.
Real-time PCR analyses
For real-time PCR, the total RNA was isolated using Trizol Reagent
(Invitrogen) and subsequently purified by ethanol precipitation.
Quantitative TaqMan PCR analysis was carried out with the ABI
PRISM 7900HT Sequence Detection System (Applied Biosystems) using
a TaqMan One-Step RT-PCR Master Mix Reagents Kit (Applied
Biosystems) in a reaction volume of 20ml containing 2mg purified
RNA, 1 Master Mix without UNG, 1 MultiScribe and RNase
Inhibitor Mix and 1 probes and primer sets Hs00332747_m1
(KIAA1456) (TaqMan Gene Expression Assays) or 1 HuGAPDH (Pre-
Developed TaqMan Assay Reagents) according to manufacturer’s
protocol. The following Thermal Cycler parameters were used:
incubation at 488C for 30min (RT-step), denaturation at 958C for
10min, followed by 40 cycles of the amplification step (denaturation
at 958C for 15 s and annealing/extension at 608C for 1min). All
amplification reactions were performed in triplicate and the relative
quantification of KIAA1456 (hTRM9L) gene expression was determined
after normalization with the endogenous control, GAPDH. Data
processing and statistical analyses were performed using the ABI
PRISM SDS, software version 2.1 (Applied Biosystems). All mRNA data
points specific to cancer lines and xenograft tumour samples represent
the average of independent biological samples (N¼3), with error bars
representing standard deviations and statistical significance deter-
mined using a Student’s t-test.
TissueScan human cancer panel
KIAA1456 (hTRM9L) expression profiling was performed using
TissueScan Cancer qPCR arrays (384 format) from OriGene (OriGene
Technologies, Inc., Rockville, MD, USA). The qPCR array consisted of
panels of normalized first-strand complementary DNA (cDNA) from 18
different pathologist-verified human cancer tissues (with cancer stage
ranging between I to IV). The array also included samples derived from
normal tissues. Quantitative PCR analysis was carried out with the
ABI PRISM 7900HT System (Applied Biosystems) and the expression
level of hTRM9L in these cancer tissues was examined using the
primer set Hs00332747_m1 (KIAA1456/hTRM9L) (TaqMan Gene
Expression Assays) after normalization with the control gene Sybr-
Green b-actin (Origene-supplied primer pair) according to manufac-
turer’s protocol. For the tumour array panel we used technical
replicates (N¼3) of each patient sample to generate average values.
The average value from each tumour sample in a cancer subtype for
each patient was compared to matched normal tissue using a
Student’s t-test.
Xenografts: chick chorioallantoic assay (CAM Assay) and nude
mice
Fertilized White Leghorn chicken eggs (Charles River, MA)
were incubated for 10 days at 378C in a humidified atmosphere
inside a hatching incubator equipped with an automatic
rotator (Octagon 20, Brinsea, Somerset, UK). On the day of the
experiment, each eggshell was punctured in two locations: one on the
long side of the egg and one on the side over the natural air sac. By
using a suction device, an artificial air sac was created to separate the2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 379
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380CAM from the eggshell. A square window of 1 cm was opened over
the displaced CAM and sealed with a piece of sterile tape. GFP labeled
SW620 cells expressing b-galactosidase or hTRM9L were detached
from the plate with 2mM EDTA in PBS and washed twice in PBS. Cells
(5105) were resuspended in 50ml PBS containing 1mM MgCl2,
0.5mM CaCl2, 100U/ml penicillin and 100mg/ml streptomycin and
then inoculated per CAM. The opening was re-sealed with tape and
the eggs were placed in a stationary incubator at 378C for 7 days or as
indicated. The resulting tumours were excised and minced in a clean
petri dish, then collagenased (type IA, Sigma) for 30min at 378C. The
number of tumour cells was counted with a haemacytometer. For
nude mouse studies, SW620-LacZ, SW620-hTRM9L, HCT116-LacZ
and HCT116-hTRM9L cells were detached with 2mM EDTA, counted,
and 3.75105 cells in 100ml of PBS were injected subcutaneously
into the interscapular and flank regions of 4- to 6-week-old BALB/c
nu/nu mice (Charles River, Wilmington, MA). Tumours were measured
every 2 days or upon completion of the experiment. Tumour volumes
were calculated using the formula (D d2)/2, where D is the longest
and d is the shortest diameter. Animals were sacrificed at 7 weeks.
Tumours were flash frozen for transgene detection or fixed in 10%
formalin and embedded in paraffin. All data points represent
independent biological samples (N¼3), with error bars representing
standard deviations and statistical significance determined using a
Mann–Whitney test.
Detection of disseminated SW620 cells via Alu-qPCR
SW620 overexpressing hTRM9 or LacZ cells were inoculated into
CAMs (for details see (Kim et al, 1998) and allowed to grow for 3 days.
Livers were collected and incubated with collagenase. DNA was
extracted using the Extract-N-Amp kit from Sigma (XNAT2-1KT).
Human Alu (hAlu) sequences were detected by quantitative-PCR. The
primers for hAlu sequences were: hAlu sense (ACGCCTGTAATCCCAG-
CACTT) and hAlu antisense (TCGCCCAGGCTGGGTGCA). Each assay
included a negative control (chicken tissue that has not been
injected with human cells,) a positive control (human genomic
DNA from SW620 tumour), and the experimental samples in
triplicate.
Fluorescence-activated cell sorting analysis
Cells recovered from CAM tumour tissues after collagenase treatment
were washed in DMEM and resuspended in PBS, followed by Percoll
purification. GFP-labeled and unlabeled SW620 cells from culture
served as controls. Samples were filtered through 35mm mesh cell
strainers (Becton Dickinson) before sorting. GFP-positive cells were
collected with a FACSAria machine (Becton Dickinson, San Jose, CA).
Data collection was performed with FACSDiva software. On average,
between 2104 and 1105 GFP-positive cells were collected. Total
RNA of the GFP-positive population was immediately isolated using
Trizol LS Reagent (Invitrogen) and subsequently purified by ethanol
precipitation. RNA was prepared for microarray analysis using the WT-
Ovation Pico RNA amplification system and hybridized to Affymetrix
GeneChip Human Gene 1.0 ST arrays using standard protocols
(Microarray Core Facility, Center for Functional Genomics, University
at Albany). Validation of the Microarray gene expression analysis data
was carried out by the quantitative TaqMan PCR assay (Applied
Biosystems) using TaqMan Gene Expression Master Mix Reagent Kit
according to manufacturers protocols. Following TaqMan Gene 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.Expression primer sets were used: Hs00332747_m1 (KIAA1456/
hTRM9L), Hs00267016_m1 (POR), Hs00167441_m1 (ALAS1),
Hs00542748_m1 (LIN9) or 1 HuGAPDH (Pre-Developed TaqMan
Assay Reagents). All data points represent independent biological
samples (N¼3), with error bars representing standard deviations and
statistical significance determined using a Student’s t-test.
Colony formation assay
SW620-LacZ and -hTRM9L expressing cells were seeded at a density
of 50 cells per well in a 12-well culture dish and cultured for 12 days
under either normoxic (21% oxygen) or hypoxic (1% oxygen)
conditions. Cells were fixed and stained with crystal violet (Fig 5).
All data points represent independent biological samples (N¼3) with
the average value and standard deviation (error bars) shown in
Figures 1F, 2 and 4A.
Immunohistochemistry (IHC) and immunocytochemistry (ICC)
For anti-phospho histone 3 (pH3), cleaved Caspase-3, LC-3, p21, p27
and GLUT1 IHC, tumours were embedded in an O.T.C. compound,
sectioned at 8.0mm, mounted on Superfrost Plus Slides and fixed in
100% ethanol. The day before immunostaining, the sections were
hydrated overnight in a humidified incubator at 378C. Sections were
washed with PBS for 5min, permeabilized with 0.5% Triton-X in PBS
for 10min, endogenous peroxides were inactivated with 3% hydrogen
peroxide for 20min and blocked with normal goat serum in PBS for
1 h. They were then incubated with the primary antibodies at a
dilution of 1:100 overnight at 48C except for Glut-1 that was used at a
dilution of 1–5000. The GLUT1 antibody (Millipore – 07-1401) was a
kind gift from Dr. David Burstein (Mount Sinai School of Medicine).
Antibodies to Cleaved caspase-3 (Asp175), p-histone H3 (S10),
p21CIP1, p27KIP were from Cell Signalling Technology and to LC-3
from Axxora, LLC. The biotinylated secondary antibody (Vectastain Elite
ABC Kit) was then added and sections incubated for 1 h at RT and
detected using a Vectastain ABC Kit following vendor’s protocol.
Diaminobenzidine solution was then added and sections were
incubated for 5min at room temperature, or until acceptable colour
intensity had been reached, after which they were rinsed with
deionized water. The nuclei were counterstained with Haematoxilin.
For HIF1-a IHC, SW620 LacZ and hTRM9L-expressing cells were
grown on cover slips in 35mm culture dishes (MatTek). Twenty-four
hours after exposure to either normoxic or hypoxic conditions, cells
were fixed with 4% formaldehyde in PBS for 15min. Fixed cells were
permeabilized and incubated with monoclonal mouse Anti-Human
HIF-1a (BD Pharmingen) at a dilution of 1:200 for 2 h. Mouse Anti
HIF-1a was detected with Alexa Fluor 488 conjugated goat anti-
mouse secondary antibody (Invitrogen) at a dilution of 1:800. Cover
slips were mounted with ProLong Gold Antifade Reagent with DAPI
nuclear stain (Invitrogen). Fluorescent images were obtained by using
a Leica TCS SP5 II confocal inverted microscope with a 63 objective.
All data points represent independent biological samples (N¼3), with
error bars representing standard deviations and statistical significance
determined using a Student’s t-test.
Cytochemical detection of b-galactosidase staining
Cells from tumour nodules in vivo were attached to poly-L-lysine
(Sigma)-coated cover slips fixed with 2% formaldehyde, 0.2% glutar-
aldehyde solution for 15min. Fixed cells were then stained forEMBO Mol Med (2013) 5, 366–383
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The paper explained
PROBLEM:
The 5-year survival rate for many late stage cancers is very low,
as exemplified for stage IV colorectal cancer (8%), and new
treatment options are desperately needed to stop this disease.
Cancer cells in late-stage tumours have turned off important
growth inhibitory pathways and deciphering the molecular
mechanisms that regulate tumour growth can provide insights
for viable therapeutic interventions.
RESULTS:
We have demonstrated that the human tRNA methyltransferase
9-like (hTRM9L) gene is turned off in breast, bladder, testicular,
cervical and colon cancers. Modeling this finding in cells derived
from late stage colorectal cancers, we demonstrate that
reactivation of hTRM9L and its corresponding methyltransferase
activity can prevent tumour growth. This occurs via upregulation
of LIN9, a known tumour suppressor, and by inhibiting the
hypoxic response. Further, we show that hTRM9L deficient
colorectal cancer cells are susceptible to killing by amino-
glycoside antibiotics and linked this susceptibility to altered
tRNA modification levels.
IMPACT:
Aminoglycoside antibiotics are already approved by the Food and
Drug Administration to treat gram-positive bacterial infections.
Our study suggests that these drugs could be re-purposed to treat
some late stage cancers deficient in hTRM9L. Further, hTRM9L
levels could serve as a biomarker of susceptibility to these
antibiotics, providing a personalized targeted therapy.the presence of b-galactosidase at pH 6.0 using the Senescence
b-galactosidase Staining Kit (Cell Signalling) according to the
manufactures protocol. The number of positive stained cells was
scored using a Nikon Eclipse TS100 microscope. All data points
represent independent biological samples (N¼3), with average values
shown and error bars representing standard deviations. Statistical
significance was determined using a Student’s t-test.
MSD detection of Hif1-a protein levels
Three-day-old tumours were excised from the CAM, minced and
resuspended in 0.5ml of Tris Lysis buffer containing 2 Protease
Inhibitor Cocktail (supplied by manufacturer) and then processed on
ice using a hand-held tissue homogenizer. Samples were incubated
on ice for 15min before separating the protein extract from cell debris
by spinning them for 10min in a microcentrifuge at 14,000 rpm at
48C. Protein concentrations were determined by the Bradford assay. A
96-Well MULTI-ARRAY Total HIF1-a Assay was purchased from Meso
Scale Discovery (Gaithersburg, MD) and completed according to
manufacturer’s protocol using 20mg of total protein. After a 1 h
incubation, wells were washed again and 1 MSD Read Buffer was
added and plate was analysed immediately by the MSD Sector 2400.
All data points represent independent biological samples (N¼3). The
average value is noted with error bars representing standard
deviations.
Quantification of tRNA modifications
The quantification of RNA modifications in tRNA by liquid-chromato-
graphy-coupled mass spectrometry (LC-MS/MS) was performed as
described previously (Chan et al, 2010) with several modifications.
Following enzymatic hydrolysis and dephosphorylation of purified
tRNA, ribonucleosides were resolved on a Thermo Scientific Hypersil
GOLD aQ reverse-phase HPLC column (1502.1mm, 3mm particle
size) eluted with the following gradient of acetonitrile in 8mM
ammonium acetate at a flow rate of 0.3ml/min and 368C: 0–18min,
0%; 18–23min, 0–1%; 23–28min, 1–6%; 28–30min, 6%; 30–EMBO Mol Med (2013) 5, 366–383 40min, 6–100%; 40–50min, 100%. The HPLC column was coupled
to an Agilent 6410 Triple Quadrupole mass spectrometer with an
electrospray ionization source operated in positive ion mode with the
following parameters for voltages and source gas: gas temperature,
3508C; gas flow, 10 L/min; nebulizer, 20 psi; and capillary voltage,
3500 V. The first and third quadrupoles (Q1 and Q3) were fixed to unit
resolution and the modifications were quantified by pre-determined
molecular transitions. Q1 was set to transmit the parent ribonucleo-
side ions and Q3 was set to monitor the deglycosylated product ions. A
dynamic MRM program was set up to monitor modified nucleosides.
The retention time, delta time, m/z of the transmitted parent ion, m/z
of the monitored product ion, fragmentor voltage, and collision energy
of each modified nucleoside are as follows: D, 2.15min, 2min,m/z
247!115, 80 V, 5 V; acp3U, 3.05min, 2min,m/z 346!214, 100 V,
10 V; Y, 3.4min, 2min, m/z 245!125; m5C, 4.87min, 2min,m/z
258!126, 80 V, 8 V; Cm, 5.62min, 2min,m/z 258!112, 80 V,
8 V;m3C, 6.33min, 2min,m/z 258!126, 80 V, 8 V; I, 6.44min,
2 min,m/z 269!137, 80 V, 10 V; m5U, 6.75 min, 2 min,m/z
259!;127, 80 V, 7 V; ac4C, 7.35min, 2min,m/z 286!154, 100 V,
10 V; ncm5U, 7.42min, 3 min,m/z 302!170, 90 V, 7 V; m7G,
7.91min, 2min,m/z 298!166, 90 V, 10 V; Um, 8.83min, 2min,m/
z 259!113, 80V, 7V; m1A, 9.33min, 2min,m/z 282!150, 100 V,
16 V; cm5s2U, 9.64min, 2min, m/z 319187; m1I, 10.17min, 2min,
m/z 283!151; mcm5U, 11.93min, 3min,m/z 317!185, 90 V,
7 V; m1G, 14.98 min, 2 min,m/z 298!166, 90 V, 10 V; m2G,
17.23min, 2min,m/z 298!166, 90 V, 10 V;m5Um, 19.68min,
2min,m/z 273!127, 100 V, 10 V; Gm, 21.39min, 3min, m/z
298!152; mcm5s2U, 28.05min, 3min,m/z 333!201, 90 V,
7 V;m22G, yW, 29.5min, 2min, m/z 509377; 30.49min, 2min, m/z
312!180, 100 V, 8 V; Am, 32.22min, 2min,m/z 282!136, 100 V,
15 V; OHyW, 36.65min, 2min,m/z 525!393, 100 V, 10 V; and i6A,
37.81min, 2min,m/z 336!204, 100 V, 17 V. All data points
represent independent biological samples (N¼3), with error bars
representing standard deviations and statistical significance deter-
mined using a Student’s t-test.2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 381
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382For more information
Oncomine details for hTRM9L (also called KIAA1456): requires free
registration:
https://www.oncomine.org/resource/main.html#dso%3AgeneOverex%
3Bec%3A%5B2%5D%3Bepv%3A150001.151078%2C3508%3Bg%
3A57604%3Bpg%3A1%3Bpvf%3A7536%5BKIAA1456%5D%3Bscr%
3Asummary%3Bv%3A13
RNA Modification Database:
http://rna-mdb.cas.albany.edu/RNAmods/
hTRM9L gene page at NCBI:
http://www.ncbi.nlm.nih.gov/gene/57604
Aguirre-Ghiso lab at MSSM:
http://www.mssm.edu/profiles/julio-a-aguirre-ghiso
Begley Lab at CNSE:
http://cnse.albany.edu/AboutUs/FacultyStaff/Faculty/ThomasBegley.aspx
Dedon lab at MIT:
http://dedon.mit.edu/
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